Welcome to LookChem.com Sign In|Join Free
  • or

50-07-7

Post Buying Request

50-07-7 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Mitomycin C/factory price/99%50KG in stock
Cas No: 50-07-7
USD $ 1.0-1.0 / Kilogram 1 Kilogram 100 Kilogram/Month Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd Contact Supplier
Mitomycin C/ LIDE PHARMA- Factory supply / Best price
Cas No: 50-07-7
No Data 1 Milligram 1 Kilogram/Day LIDE PHARMACEUTICALS LIMITED Contact Supplier
Mitomycin
Cas No: 50-07-7
USD $ 1.0-1.0 / Gram 1 Gram 100 Kilogram/Year HANWAYS CHEMPHARM CO.,LIMITED Contact Supplier
High purity 50-07-7 Mitomycin
Cas No: 50-07-7
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
CAS:50-07-7 Mitomycin C
Cas No: 50-07-7
No Data 1 Kilogram 100 Kilogram/Month Kono Chem Co.,Ltd Contact Supplier
Manufacturer supply Mitomycin C CAS 50-07-7 of USP standard
Cas No: 50-07-7
USD $ 170.0-230.0 / Gram 1 Gram 60 Kilogram/Year Wuhan Fortuna Chemical Co.,Ltd Contact Supplier
Mitomycin
Cas No: 50-07-7
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier
Factory Supply Mitomycin C
Cas No: 50-07-7
No Data 1 1 Ality Chemical Corporation Contact Supplier
Amadis Chemical offer CAS#50-07-7;CAT#A854289
Cas No: 50-07-7
No Data 10 Milligram Amadis Chemical Co., Ltd. Contact Supplier
Mitomycin C CAS NO 50-07-7
Cas No: 50-07-7
No Data 1 Kilogram 20000 Kilogram/Day Hubei XinRunde Chemical Co., Ltd Contact Supplier

50-07-7 Usage

Shipping

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials.

Manufacturing Process

The commercial production of mitomycin involves the preparation of mitomycin-containing broths by culturing a mitomycin-producing organism, e.g. Streptomyces caespitosus, in suitable media as described at length in the literature. At the end of the fermentation cycle the whole broth is usually centrifuged, filtered or otherwise treated to separate the solids (mycelia) from the supernatant which contains substantially all of the antibiotic activity.In commercial processes there is usually a period of time intervening between the end of the fermentation cycle and the time at which the mycelia is actually removed from the broth; such a period may range from several minutes to several hours in length and may be due to a number of factors, e.g., the time necessary to conduct the actual centrifugation or filtration of large quantities of broth, or the time involved in waiting for equipment to become available for use. In the commercial preparation of mitomycin, the mitomycin-containing whole broths decrease rapidly in potency during the time following the completion of the fermentation cycle and prior to the removal of the mycelia. It has been observed that a whole broth will lose substantially all of its mitomycin activity within about 6 hours at room temperature and within about 24 hours at 10°C. It has, however, been discovered, as described in US Patent 3,042,582, that in the process for the recovery of mitomycin C from mitomycin C-containing whole broth, the step of adding about 0.1 wt % with whole broth of sodium lauryl sulfate to the whole broth at the completion of the fermentation cycle substantially eliminates such destruction of mitomycin C by mitase.

Incompatibilities

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides, heat, strong light, calcium salts.

Indications

Mitomycin (mitomycin C, Mitocin-C, Mutamycin) is an antibiotic that is derived from a species of Streptomyces. It is sometimes classified as an alkylating agent because it can covalently bind to and cross-link DNA. Mitomycin is thought to inhibit DNA synthesis through its ability to alkylate double-strand DNA and bring about interstrand cross-linking. There is evidence that enzymatic reduction by a reduced nicotinamide– adenine dinucleotide phosphate (NADPH) dependent reductase is necessary to activate the drug. The drug is rapidly cleared from serum after intravenous injection but is not distributed to the brain.

Brand name

Mutamycin (Bristol-Myers Squibb);Mytozytrex (SuperGen).

Chemical properties

It is a crystalline powder or a powder with blue-purple shiny crystal. Its solid state is stable, while easily deactivated in acidic and alkaline solution. Mp> 360 ℃; the maximum absorption wavelength in methanol is 216nm, 360nm and 560nm.The maximum absorption wavelength in aqueous solution is 365nm ± 2nm. This product is soluble in water, methanol, acetone and ethyl acetate and other organic solvents, slightly soluble in benzene, ether and carbon tetrachloride, insoluble in petroleum ether. Highly toxic chemical, LD50 (rat, oral) 14mg/kg. Tests show that this product has potential carcinogenic effects on experimental animals.

Originator

Mitomycin,Medac,W. Germany,1960

General Description

administration in the treatment of cancers of the stomachand pancreas when other treatments have failed. Other useshave included breast, NSCLC, cervical, bladder, and headand neck cancers. Mechanisms of resistance include increasedsynthesis of nucleophilic detoxifying compoundssuch as glutathione, decreased expression of activating enzymessuch as DT-diaphorase, and increased efflux by Pgp.The drug is rapidly cleared from the plasma after administrationand widely distributed but does not cross the bloodbrainbarrier. The parent and metabolites are excretedmainly in the feces with an elimination half-life of 50 minutes.Adverse effects include dose-limiting myelosuppression,mild nausea and vomiting,.

Uses

(1) It is a cell division inhibitors, nucleic acid inhibitors and phage inducer; an anti-tumor drugs in clinical use. (2) This drug has a broad anti-tumor spectrum, and effective for gastric cancer, breast cancer. It has a certain effect on lung cancer, liver cancer, malignant lymphoma, Hodgkin's disease, reticular cell sarcoma, uterine cancer, leukemia, intestinal cancer and pancreatic cancer, but with a short remission. Combination with urokinase can improve the efficacy. The goods exert its function quickly, but the number of operators is not high, and it has a high toxicity. The goods and bleomycin as well as its derivatives ——doxorubicin are anti-cancer drugs of antibiotic which can disrupt DNA. It can depolymerize DNA in the cell, inhibit DNA replication in proliferating cell. The LD50 of intravenous injection of mice is 5ml/kg. It acts as an anticancer drugs, commonly used in the treatment of digestive system cancers.

Health Hazard

Toxic doses as low as 750 mg/kg have been reported in humans. The major toxic effect is myelosuppression, characterized by marked leukopenia and thrombocytopenia; this may be delayed and cumulative. Interstitial pneumonia and glomerular damage resulting in kidney failure are unusual but well documented complications. Lung conditions -- administration of mitomycin has been recognized as causing pneumonitis, alveolitis and pulmonary fibrosis. Kidney conditions -- administration of Mitomycin Can cause kidney damage. Kidney toxicity was observed in 1-5 percent of patients. Depressed immune conditions.

Uses

Mitomycin C is the most studied of a family of highly distinctive blue/purple metabolites produced by several Streptomyces species. Mitomyin C exhibits potent antibacterial and antitumour activity and inhibits DNA synthesis by intercalation, blocking nuclear division with the induction of apoptosis in cancer cells.

General Description

Mitomycin C was isolated from Streptomyces caespitosus in 1958 by Japanese workers and is considered the prototype of the bioreductive alkylating agents. Mitomycin is sometimes included as an alkylating agent but is included here because. It was reasoned that selective activation could be achieved in a reductive environment such as that found in an area of low oxygen content. This is known to occur in tumors where the fast-growing cells often grow beyond the blood supply that would normally provide oxygen. Mitomycin C is capable of being activated and alkylating DNA in an anaerobic environment. The drug contains what would appear to be reactive functionalities, including the quinone and aziridine functionalities, both or which would be thought to be susceptible to nucleophilic attack; however, the reactivity of these functionalities is reduced because of steric and electronic effects in the parent molecule. It was reasoned that selective activation could be achieved in a reductive environment such as that found in an area of low oxygen content. This is known to occur in tumors where the fast-growing cells often grow beyond the blood supply that would normally provide oxygen.A normal cell would undergo apoptosis under these conditions, but because cancer cells often have their apoptotic mechanisms inhibited they continue to survive with little or no oxygen available. Mitomycin C is capable of being activated and alkylating DNA in an anaerobic environment, but there is actually little selectivity for hypoxic cells. Activation can occur enzymatically by both one- and twoelectron processes. Reductive enzymes such as NADPHCYP reductase and DT-diaphorase have been implicated in these processes.Involvement of one-electron processes such as those seen for the anthracylines result in redox cycling and the production of ROS that may result in DNA damage, but the cytotoxicity of mitomycin C is primarily associated with its ability to alkylate DNA.

Side effects

The major toxicity associated with mitomycin therapy is unpredictably long and cumulative myelosuppression that affects both white blood cells and platelets. A syndrome of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure also has been described. Renal, hepatic, and pulmonary toxicity may occur. The drug is teratogenic and carcinogenic, and it can cause local blistering.

Biological Activity

Antibiotic and antitumor agent. Covalently binds DNA forming intra- and interstrand crosslinks. Inhibits DNA synthesis.

Chemical Properties

Mitomycin is a blue-violet crystalline solid.

Hazard

Possible carcinogen.

Uses

Mitomycin C USP (Mutamycin) is used to treat chronic myelogenous leukemia; reticulum cell sarcoma; Hodgkin.s disease; non-Hodgkin.s lymphomas; cancer of stomach, pancreas, lung; epithelial tumors.

Metabolism

Mitomycin is administered IV in the treatment of disseminated adenocarcinoma of the stomach or pancreas, and it has been used intravesically in superficial bladder cancer. Biotransformation pathways are saturable, and approximately 10% of an administered dose is eliminated unchanged via the kidneys.

Fire Hazard

Flash point data for Mitomycin C are not available; however, Mitomycin C is probably combustible.

Clinical Use

Mitomycin has limited palliative effects in carcinomas of the stomach, pancreas, colon, breast, and cervix.

description

Mitomycin C (MMC), an antineoplastic antibiotic derived from Streptomyces caespitosus or Streptomyces lavendulae, is a cell cycle-specific alkylating agent, inhibits DNA synthesis through covalent mitomycin C-DNA adduct with EC50 values of 0.14μM in PC3 cells. Therefore, it was served as a chemotherapeutic agent that has demonstrated its antitumor activity and has been used widely in treatment of various cancers. Although it is active against a wide variety of tumors, newer agents have largely replaced MMC except in anal cancer; outside of the United States, MMC is infrequently used for treatment of advanced non-small cell lung cancer (NSCLC), and breast cancer.

Side effects

As with many other chemotherapeutic agents, most of the side effects of Mitomycin C (MMC)? are dose-related, including myelosuppression (which is typically delayed in onset), nausea, vomiting, diarrhea, stomatitis, dementia, and alopecia. Pulmonary toxicity associated with MMC is unpredictable, but more likely to occur at higher doses. The following side effects are common (occurring in greater than 30%) for patients taking Mitomycin C: Low blood counts.? Your white and red blood cells and platelets may temporarily decrease.? This can put you at increased risk for infection, anemia and/or bleeding.? The nadir counts are delayed with this drug. Nadir: Meaning low point, nadir is the point in time between chemotherapy cycles in which you experience low blood counts. Onset: 3 weeks Nadir: 4-6 weeks Recovery: 6-8 weeks Mouth sores Poor appetite Fatigue These side effects are less common side effects (occurring in about 10-29%) of patients receiving Mitomycin C: Nausea and vomiting, usually mild Diarrhea Hair loss Bladder inflammation (urinary frequency, burning, cramping, pain)-seen with intravesical (into the bladder) therapy.

Definition

Antibiotic derivedfrom Streptomyces, stated to be effective againsttumors.

Chemical Properties

Blue-violet crystals or crystalline powder.

Waste Disposal

Consult with environmental regulatory agencies for guidance on acceptable disposal practices. Generators of waste containing this contaminant (≥100 kg/mo) must conform to EPA regulations governing storage, transportation, treatment, and waste disposal. It is inappropriate and possibly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged, and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Potential Exposure

This compound is an antitumor antibiotic complex. This drug is usually injected intravenously.

General Description

Blue-violet crystals. Used as an anti-tumor antibiotic complex.

Purification Methods

Mitomycin C forms blue-violet crystals from *C6H6/pet ether. It is soluble in Me2CO, MeOH and H2O, moderately soluble in *C6H6, CCl4 and Et2O but insoluble in pet ether. It has UV max at 216, 360 and a weak peak at 560nm in MeOH. [Stevens et al. J Med Chem 8 1 1965, Shirahata & Hirayama J Am Chem Soc 105 7199 1983, Beilstein 25 III/IV 516.]

Reactivity Profile

Mitomycin C is sensitive to prolonged exposure to light. Mitomycin C may be sensitive to prolonged exposure to air. Mitomycin C is incompatible with strong oxidizing agents, strong acids and strong bases. Calcium salts may cause decomposition.

Uses

An antitumor antibiotic. It is used as antineoplastic.

Air & Water Reactions

Water soluble.

Therapeutic Function

Cancer chemotherapy
InChI:InChI=1/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7?,13+,15-/m0/s1

50-07-7 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
TCI America (M2320)  Ametycin  >98.0%(HPLC) 50-07-7 10mg 590.00CNY Detail
TCI America (M2320)  Ametycin  >98.0%(HPLC) 50-07-7 50mg 1,590.00CNY Detail

50-07-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name Mitomycin C

1.2 Other means of identification

Product number -
Other names Ametycine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:50-07-7 SDS

50-07-7Synthetic route

albomitomycin A
110934-24-2

albomitomycin A

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With ammonia at 25℃; for 0.5h;99%
Multi-step reaction with 2 steps
1: 1) H2, 2) air / 1) 10percent Pd on carbon / 1) acetonitrile, 1 atm, 25 deg C, 2 h, 2) 25 deg C, 2 h
2: 75 percent / 6 M methanol. NH3 / 5 h / 25 °C
View Scheme
2-((2-(piperidin-1-yl)ethyl)disulfanyl)ethyl(1aS,8S,8aR,8bS)-6-amino-8-((carbamoyloxy)methyl)-8a-methoxy-5-methyl-4,7-dioxo-1a,4,7,8,8a,8b-hexahydroazirino [2’,3’:3,4]pyrrolo[1,2-a]indole-1(2H)-carboxylate

2-((2-(piperidin-1-yl)ethyl)disulfanyl)ethyl(1aS,8S,8aR,8bS)-6-amino-8-((carbamoyloxy)methyl)-8a-methoxy-5-methyl-4,7-dioxo-1a,4,7,8,8a,8b-hexahydroazirino [2’,3’:3,4]pyrrolo[1,2-a]indole-1(2H)-carboxylate

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With l-cysteine hydrochloride In ethanol; water at 37℃; for 2h;92%
1a-acetyl-7-demethoxy-6,7-dihydro-7,7-(ethylenedioxy)-6-(phenylselenyl)mitomycin A
122644-74-0, 122675-60-9, 134679-23-5

1a-acetyl-7-demethoxy-6,7-dihydro-7,7-(ethylenedioxy)-6-(phenylselenyl)mitomycin A

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With ammonia; dimedone In methanol Ambient temperature;81%
7-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)-9a-methoxymitosane
128583-70-0

7-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)-9a-methoxymitosane

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With ammonium hydroxide In methanol for 0.5h; Ambient temperature;80%
isomitomycin A
91917-64-5

isomitomycin A

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With ammonia at 25℃; for 5h;75%
7-<<(dimethylamino)methylene>amino>-N10-<(dimethylamino)methylene>-9a-methoxymitosane
88948-91-8

7-<<(dimethylamino)methylene>amino>-N10-<(dimethylamino)methylene>-9a-methoxymitosane

Benzhydrylamine
91-00-9

Benzhydrylamine

A

mitomycin C
50-07-7

mitomycin C

B

7-<<(dimethylamino)methylene>amino>-9a-methoxymitosane
88949-01-3

7-<<(dimethylamino)methylene>amino>-9a-methoxymitosane

C

7-<(diphenylmethyl)amino>-9a-methoxymitosane
110971-78-3

7-<(diphenylmethyl)amino>-9a-methoxymitosane

Conditions
ConditionsYield
In methanol at 54℃; for 4h;A 20%
B 41%
C 8%
2-(2-Pyridinyldithio)benzylmitomycin C-1a-carboxylate
126900-78-5

2-(2-Pyridinyldithio)benzylmitomycin C-1a-carboxylate

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With diothiothreitol In methanol; water at 30℃; pH 7.2; other (2-pyridinyldithio)benzyl MMC-1a-carboxylates;
7-<<(dimethylamino)methylene>amino>-9a-methoxymitosane
88949-01-3

7-<<(dimethylamino)methylene>amino>-9a-methoxymitosane

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With phsphate buffer In water at 45℃; Rate constant; Mechanism; pH 6.5, other pH, other buffer, other temperature;
leucomitomycin C
92056-69-4

leucomitomycin C

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With oxygen In ethanol
C15H18N4O6

C15H18N4O6

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With methanol; water at 20℃; Irradiation;
C19H26N4O6

C19H26N4O6

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With methanol; water at 20℃; Irradiation;
C16H20N4O6

C16H20N4O6

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With methanol; water at 20℃; Irradiation;
With water In methanol; ethyl acetate Mechanism; Irradiation; other mitomycin C derivatives;
(8aS)-8a-bromoalbomitomycin A
132732-87-7, 132830-44-5

(8aS)-8a-bromoalbomitomycin A

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / tributyltin hydride, AIBN / toluene / 0.17 h / 60 °C
2: 99 percent / 6 M methanol. NH3 / 0.5 h / 25 °C
View Scheme
Multi-step reaction with 3 steps
1: 85 percent / tributyltin hydride, AIBN / toluene / 0.17 h / 60 °C
2: 1) H2, 2) air / 1) 10percent Pd on carbon / 1) acetonitrile, 1 atm, 25 deg C, 2 h, 2) 25 deg C, 2 h
3: 75 percent / 6 M methanol. NH3 / 5 h / 25 °C
View Scheme
(8aR)-8a-bromoalbomitomycin A
132732-87-7, 132830-44-5

(8aR)-8a-bromoalbomitomycin A

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 54 percent / H2, NaHCO3 / 5percent Pd on BaSO4 / methanol; H2O / 0.17 h / 25 °C
2: 99 percent / 6 M methanol. NH3 / 0.5 h / 25 °C
View Scheme
Multi-step reaction with 3 steps
1: 54 percent / H2, NaHCO3 / 5percent Pd on BaSO4 / methanol; H2O / 0.17 h / 25 °C
2: 1) H2, 2) air / 1) 10percent Pd on carbon / 1) acetonitrile, 1 atm, 25 deg C, 2 h, 2) 25 deg C, 2 h
3: 75 percent / 6 M methanol. NH3 / 5 h / 25 °C
View Scheme
Multi-step reaction with 3 steps
1: K2CO3 / acetonitrile / 24 h / 25 °C
2: 85 percent / tributyltin hydride, AIBN / toluene / 0.17 h / 60 °C
3: 99 percent / 6 M methanol. NH3 / 0.5 h / 25 °C
View Scheme
Multi-step reaction with 4 steps
1: K2CO3 / acetonitrile / 24 h / 25 °C
2: 85 percent / tributyltin hydride, AIBN / toluene / 0.17 h / 60 °C
3: 1) H2, 2) air / 1) 10percent Pd on carbon / 1) acetonitrile, 1 atm, 25 deg C, 2 h, 2) 25 deg C, 2 h
4: 75 percent / 6 M methanol. NH3 / 5 h / 25 °C
View Scheme
CHCl3-MeOH

CHCl3-MeOH

mitomycin A
4055-39-4

mitomycin A

mitomycin C
50-07-7

mitomycin C

C256H490N4O123S2

C256H490N4O123S2

A

carbon dioxide
124-38-9

carbon dioxide

B

4-mercaptobenzyl alcohol
53339-53-0

4-mercaptobenzyl alcohol

C

mPEG5000-SH

mPEG5000-SH

D

mitomycin C
50-07-7

mitomycin C

Conditions
ConditionsYield
With N-acetylcystein at 37℃; pH=4.5; Kinetics; pH-value;
methyl chlorodithioformate
16696-91-6

methyl chlorodithioformate

mitomycin C
50-07-7

mitomycin C

7-amino-9a-methoxy-1a-<(methylthio)thiocarbonyl>mitosane
109334-26-1

7-amino-9a-methoxy-1a-<(methylthio)thiocarbonyl>mitosane

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane at 80℃; for 1h;95%
phenyl chlorothioformate
13464-19-2

phenyl chlorothioformate

mitomycin C
50-07-7

mitomycin C

7-amino-9a-methoxy-1a-<(phenylthio)carbonyl>mitosane
109334-21-6

7-amino-9a-methoxy-1a-<(phenylthio)carbonyl>mitosane

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane at 45℃; for 1h;95%
mitomycin C
50-07-7

mitomycin C

trifluoroacetic acid
76-05-1

trifluoroacetic acid

A

1β-hydroxy-2β-trifluoroacetamido-7-aminomitosene
111602-68-7

1β-hydroxy-2β-trifluoroacetamido-7-aminomitosene

B

Carbamic acid (1R,2S)-2-acetylamino-7-amino-1-hydroxy-6-methyl-5,8-dioxo-2,3,5,8-tetrahydro-1H-pyrrolo[1,2-a]indol-9-ylmethyl ester
55253-24-2

Carbamic acid (1R,2S)-2-acetylamino-7-amino-1-hydroxy-6-methyl-5,8-dioxo-2,3,5,8-tetrahydro-1H-pyrrolo[1,2-a]indol-9-ylmethyl ester

Conditions
ConditionsYield
With urethane Mechanism; Product distribution; multistep;A 95%
B 5%
With urethane 1.) MeCN, RT; Yield given. Multistep reaction;A n/a
B 5%
(4-nitrophenyl) [4-(2-pyridyldisulfanyl)phenyl]methyl carbonate
1151989-04-6

(4-nitrophenyl) [4-(2-pyridyldisulfanyl)phenyl]methyl carbonate

mitomycin C
50-07-7

mitomycin C

4-(2-Pyridinyldithio)benzylmitomycin C-1a-carboxylate
126900-80-9

4-(2-Pyridinyldithio)benzylmitomycin C-1a-carboxylate

Conditions
ConditionsYield
With dmap In N,N-dimethyl-formamide at 0 - 20℃; for 5h; Inert atmosphere;95%
With dmap In N,N-dimethyl-formamide at 20℃;83%
mitomycin C
50-07-7

mitomycin C

methyl thiochloroformate
18369-83-0

methyl thiochloroformate

7-amino-9a-methoxy-1a-<(methylthio)carbonyl>mitosane
109334-22-7

7-amino-9a-methoxy-1a-<(methylthio)carbonyl>mitosane

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane at 45℃; for 1h;94%
mitomycin C
50-07-7

mitomycin C

phenyl isocyanate
103-71-9

phenyl isocyanate

7-amino-9a-methoxy-1a-(phenylcarbamoyl)mitosane
109334-19-2

7-amino-9a-methoxy-1a-(phenylcarbamoyl)mitosane

Conditions
ConditionsYield
In 1,2-dimethoxyethane at 45℃; for 1h;92%
mitomycin C
50-07-7

mitomycin C

10-decarbamoyl mitomycin C
26909-37-5

10-decarbamoyl mitomycin C

Conditions
ConditionsYield
With sodium methylate In methanol; benzene for 48h; Ambient temperature;90%
With sodium methylate In methanol; benzene for 12h; Ambient temperature;80%
With sodium methylate In methanol; benzene80%
With sodium methylate In toluene80%
glutaric anhydride,
108-55-4

glutaric anhydride,

mitomycin C
50-07-7

mitomycin C

1a-(4-carboxybutyryl)-mitomycin C

1a-(4-carboxybutyryl)-mitomycin C

Conditions
ConditionsYield
In tetrahydrofuran at 60℃; for 10h; Acylation;90%
mitomycin C
50-07-7

mitomycin C

phenyl chloroformate
1885-14-9

phenyl chloroformate

7-amino-9a-methoxy-1a-(phenoxycarbonyl)mitosane
109334-17-0

7-amino-9a-methoxy-1a-(phenoxycarbonyl)mitosane

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane at 45℃; for 1h;89%
methanol
67-56-1

methanol

mitomycin C
50-07-7

mitomycin C

1a-acetyl-7-demethoxy-6,7-dihydro-7,7-(ethylenedioxy)mitomycin A
119411-13-1

1a-acetyl-7-demethoxy-6,7-dihydro-7,7-(ethylenedioxy)mitomycin A

Conditions
ConditionsYield
With ammonia88%
phenyl chlorodithioformate
16911-89-0

phenyl chlorodithioformate

mitomycin C
50-07-7

mitomycin C

7-amino-9a-methoxy-1a-<(phenylthio)thiocarbonyl>mitosane
109334-25-0

7-amino-9a-methoxy-1a-<(phenylthio)thiocarbonyl>mitosane

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane at 70℃; for 3h;88%
mitomycin C
50-07-7

mitomycin C

methyl chloroformate
79-22-1

methyl chloroformate

7-amino-9a-methoxy-1a-(methoxycarbonyl)mitoane
109334-18-1

7-amino-9a-methoxy-1a-(methoxycarbonyl)mitoane

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane at 45℃; for 1h;88%
mitomycin C
50-07-7

mitomycin C

methyl isocyanate
624-83-9

methyl isocyanate

7-amino-9a-methoxy-1a-(methylcarbamoyl)mitosane
109334-20-5

7-amino-9a-methoxy-1a-(methylcarbamoyl)mitosane

Conditions
ConditionsYield
In 1,2-dimethoxyethane at 45℃; for 1h;86%
mitomycin C
50-07-7

mitomycin C

phenylcarbonochloridothioate
1005-56-7

phenylcarbonochloridothioate

7-amino-9a-methoxy-1a-(phenoxythiocarbonyl)mitosane
109334-23-8

7-amino-9a-methoxy-1a-(phenoxythiocarbonyl)mitosane

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane at 45℃; for 1h;85%
mitomycin C
50-07-7

mitomycin C

mitomycin A
4055-39-4

mitomycin A

Conditions
ConditionsYield
With potassium hydroxide In methanol84%
mitomycin C
50-07-7

mitomycin C

7-hydroxy-9a-methoxymitosane
7041-61-4

7-hydroxy-9a-methoxymitosane

Conditions
ConditionsYield
With sodium hydroxide at 20℃; for 4h;84%
With alkaline solution In water Kinetics;
mitomycin C
50-07-7

mitomycin C

methanesulfonyl chloride
124-63-0

methanesulfonyl chloride

N(1a)-(methanesulfonyl)mitomycin C
5091-31-6

N(1a)-(methanesulfonyl)mitomycin C

Conditions
ConditionsYield
With pyridine; triethylamine at 0℃; for 0.333333h;80%
mitomycin C
50-07-7

mitomycin C

β-styrenesulfonyl chloride
4091-26-3

β-styrenesulfonyl chloride

<1aS-(1a4a,8β,8aα,8bα)>-6-amino-8-<<(aminocarbonyl)oxy>methyl>-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-1-(styryl)sulfonylazilidino<2',3':3,4>pyrrolo<1,2-a>indole-4,7-dione

<1aS-(1a4a,8β,8aα,8bα)>-6-amino-8-<<(aminocarbonyl)oxy>methyl>-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-1-(styryl)sulfonylazilidino<2',3':3,4>pyrrolo<1,2-a>indole-4,7-dione

Conditions
ConditionsYield
With pyridine for 1.5h; Ambient temperature;77%
mitomycin C
50-07-7

mitomycin C

phenyl isothiocyanate
103-72-0

phenyl isothiocyanate

7-amino-9a-methoxy-1a-(phenylthiocarbamoyl)mitosane
18887-04-2

7-amino-9a-methoxy-1a-(phenylthiocarbamoyl)mitosane

Conditions
ConditionsYield
In 1,2-dimethoxyethane for 6.5h; Heating;73%
mitomycin C
50-07-7

mitomycin C

p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

N(1a)-(toluenesulfonyl)mitomycin C
5091-32-7

N(1a)-(toluenesulfonyl)mitomycin C

Conditions
ConditionsYield
With pyridine; triethylamine at 0℃; for 0.333333h;70%
mitomycin C
50-07-7

mitomycin C

2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate
14152-97-7

2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate

N-(tetra-O-acetylglucopyranosyl)-1a-mitomycin C carbothioamide
132059-46-2

N-(tetra-O-acetylglucopyranosyl)-1a-mitomycin C carbothioamide

Conditions
ConditionsYield
In tetrahydrofuran Ambient temperature;65%
mitomycin C
50-07-7

mitomycin C

N,N-dimethyl-formamide dimethyl acetal
4637-24-5

N,N-dimethyl-formamide dimethyl acetal

7-amino-N10-<(dimethylamino)methylene>-9a-methoxymitosane
88948-99-6

7-amino-N10-<(dimethylamino)methylene>-9a-methoxymitosane

Conditions
ConditionsYield
In methanol; chloroform at 50℃; for 0.833333h;64%
mitomycin C
50-07-7

mitomycin C

A

cis-1-hydroxy-2-acetamido-7-aminomitosene
54911-22-7

cis-1-hydroxy-2-acetamido-7-aminomitosene

B

2β,7-Diamino-1α-hydroxymitosene
99745-88-7

2β,7-Diamino-1α-hydroxymitosene

C

2β,7-Diamino-1β-hydroxymitosene
98462-75-0

2β,7-Diamino-1β-hydroxymitosene

D

2,7-Diaminomitosene
92695-32-4

2,7-Diaminomitosene

Conditions
ConditionsYield
With Tris-HOAc-buffer pH 5.50; 4-methoxyphenylhydrazine hydrochloride In water for 48h; Mechanism; Ambient temperature; other substrates, also with D2O;A n/a
B n/a
C n/a
D 63%
With Tris-HOAc-buffer pH 5.50; 4-methoxyphenylhydrazine hydrochloride In water for 48h; Ambient temperature;A n/a
B n/a
C n/a
D 63%
mitomycin C
50-07-7

mitomycin C

N-allyl isothiocyanate
57-06-7

N-allyl isothiocyanate

<1aS-(1aα,8β,8aα,8bα)>-1-(allylamino)thiocarbonyl-6-amino-8-<<(aminocarbonyl)oxy>methyl>-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazilidino<2',3':3,4>pyrrolo<1,2-a>indole-4,7-dione

<1aS-(1aα,8β,8aα,8bα)>-1-(allylamino)thiocarbonyl-6-amino-8-<<(aminocarbonyl)oxy>methyl>-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazilidino<2',3':3,4>pyrrolo<1,2-a>indole-4,7-dione

Conditions
ConditionsYield
With pyridine; benzotriazol-1-ol for 18h; Ambient temperature;62%
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 50-07-7